Recombinant Human EDIL3 Protein，His

EDIL3, a member of the Epidermal Growth Factor (EGF) repeat-containing protein family, has emerged as a significant focus in cancer research due to its role in various cellular processes, including cell adhesion, migration, and proliferation. Originally identified as an important factor in the development and progression of several types of tumors, EDIL3 is known to interact with extracellular matrix components and regulate signaling pathways crucial for tumor microenvironment modulation. Studies have revealed that EDIL3 is often overexpressed in malignant tissues, contributing to the invasive and metastatic potential of cancer cells. Moreover, its expression levels have been correlated with poor clinical outcomes in patients, underscoring its potential as a prognostic marker. Researchers are increasingly interested in the functional mechanisms of EDIL3, as understanding its role may lead to novel therapeutic approaches targeting cancer metastasis. Additionally, the recombinant expression of EDIL3 protein enables the exploration of its biochemical properties and interactions, facilitating the development of inhibitors or antibodies that can disrupt its function. The ongoing investigation into EDIL3's structure-function relationship will further elucidate its contributions to tumor biology and potentially provide insights into new treatment modalities, making it a promising candidate for targeted cancer therapies.